| Name | Title | Contact Details |
|---|
Bio-Tissue®, a subsidiary of TissueTech™, is the leader in regenerative biologic therapies and ocular hygiene solutions for eye care professionals. Established in 1997, Bio-Tissue® serves an unmet need for better surgical and therapeutic alternatives for helping eye care professionals heal ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis dry eye, pterygium and dry eye. Eye care professionals understand that good medicine is based on good science. Bio-Tissue® prides itself on developing products that meet the highest clinical standards, are based on quality research and scientific data, and provide innovative solutions for a range of ocular surface and lid margin diseases. Bio-Tissue® adheres to the FDA tissue and medical device guidelines.
T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.
Established in 2005 and currently servicing over 250 clients, RetireeFirst (formerly LaborFirst) is the premier retiree benefit management solutions and advocacy service provider, proven to enhance the experience and outcomes for group plan sponsors, employers, and their retirees. Our sole focus on retiree benefits means our solutions and services, combined with our people-centric approach, deliver immediate savings, significantly reduce administrative burden, and help preserve the benefits retirees deserve. Our unparalleled retiree advocacy service connects members to programs that help improve their health and wellness, resulting in happier and more engaged members. We go above and beyond for our clients, and our Advocates give retirees a guiding hand to navigate their entire healthcare and benefits journey—ensuring peace of mind.
Established in 1946, OMRF is an independent, nonprofit biomedical research institute with more than 450 staff and over 50 labs studying cancer, heart disease, autoimmune disorders, and diseases of aging. Breakthroughs in our labs have led to three FDA-approved drugs, including the first targeted therapy approved in the U.S. for sickle cell disease and the first approved treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease. OMRF`s critical research is helping people live longer, healthier lives, one discovery at a time. Along the way, OMRF has garnered worldwide media attention, from leading scientific publications like The New England Journal of Medicine and Science to The New York Times and The Wall Street Journal. By pushing the boundaries of biomedical science, our researchers are helping to win the war against human disease, one discovery at a time.
Institute For Safe Medication Practices is a Huntingdon Valley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.